News

Researchers found that tirzepatide, a medication primarily used for treating type 2 diabetes and weight loss, reduced body ...
Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.
Now, a new study published in JAMA Network Open suggests that for people with obesity and type 2 diabetes, these drugs—known as GLP-1 receptor agonists —may also reduce the risk of death and lower the ...
GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.
(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...
Demand for glucagon-like peptide-1 weight-loss drugs — such as Ozempic, Zepbound and Wegovy — coupled with limited insurance ...
Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a ...
Landmark trials have shown that GLP-1 receptor agonists, originally developed for diabetes and weight loss, also provide ...
GLP-1 blockbusters like semaglutide and tirzepatide are widely used for diabetes and weight loss but come with some nasty ...
Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...
Researchers says the drugs could be a treatment for obese people with asthma who are ‘often resistant’ to steroids ...